O32  Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDS in rheumatoid arthritis patients: does line of therapy matter?

Conclusion Whilst initially there appears to be a difference in rates of serious infections between biologic therapies, line of therapy may be a confounding factor when comparing the risk of serious infections between bDMARDs.Disclosure K. Lauper: Honoraria; Gilead-Galapagos. Grants/research support; AbbVie. Other; AbbVie, Pfizer.L. Kearsley-Fleet: None.R. Davies: None.K. Watson: None.M. Lunt: None.K.L. Hyrich: Honoraria; AbbVie. Grants/research support; Pfizer, BMS.
Source: Rheumatology - Category: Rheumatology Source Type: research